Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Chapman

Showing results (931-940 of 1,011) with videos related to

Pageof 102
Sort By:
Nature Communications|April 30, 2015
Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturationMarianna Papaspyridonos, Irina Matei, Yujie Huang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 12, 2014
Liver involvement in early autosomal-dominant polycystic kidney diseaseMarie C Hogan, Kaleab Abebe, Vicente E Torres, et al.
Neuron|May 6, 2021
Building brain capitalHarris A Eyre, Rym Ayadi, William Ellsworth, et al.
Plos One|October 12, 2013
Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) studyCaitrin W McDonough, Nancy K Gillis, Abdullah Alsultan, et al.
Cancer Cell|November 6, 2018
Widespread Selection for Oncogenic Mutant Allele Imbalance in CancerCraig M Bielski, Mark T A Donoghue, Mayur Gadiya, et al.
Contemporary Clinical Trials|August 2, 2015
Closeout of the HALT-PKD trialsCharity G Moore, Susan Spillane, Gertrude Simon, et al.
Journal of the American Society of Nephrology : JASN|October 13, 2006
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney diseasePeter C Harris, Kyongtae T Bae, Sandro Rossetti, et al.
Cancer|August 6, 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experienceJason J Luke, Margaret K Callahan, Michael A Postow, et al.
Clinical Pharmacology and Therapeutics|September 20, 2025
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine TherapyMichael T Eadon, David W Hein, Michael A Andersen, et al.
The New England Journal of Medicine|November 18, 2014
Blood pressure in early autosomal dominant polycystic kidney diseaseRobert W Schrier, Kaleab Z Abebe, Ronald D Perrone, et al.
Pageof 102

Showing results (931-940 of 1,011) with videos related to

Sort By:
Pageof 102
Nature Communications|April 30, 2015
Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturationMarianna Papaspyridonos, Irina Matei, Yujie Huang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 12, 2014
Liver involvement in early autosomal-dominant polycystic kidney diseaseMarie C Hogan, Kaleab Abebe, Vicente E Torres, et al.
Neuron|May 6, 2021
Building brain capitalHarris A Eyre, Rym Ayadi, William Ellsworth, et al.
Plos One|October 12, 2013
Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) studyCaitrin W McDonough, Nancy K Gillis, Abdullah Alsultan, et al.
Cancer Cell|November 6, 2018
Widespread Selection for Oncogenic Mutant Allele Imbalance in CancerCraig M Bielski, Mark T A Donoghue, Mayur Gadiya, et al.
Contemporary Clinical Trials|August 2, 2015
Closeout of the HALT-PKD trialsCharity G Moore, Susan Spillane, Gertrude Simon, et al.
Journal of the American Society of Nephrology : JASN|October 13, 2006
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney diseasePeter C Harris, Kyongtae T Bae, Sandro Rossetti, et al.
Cancer|August 6, 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experienceJason J Luke, Margaret K Callahan, Michael A Postow, et al.
Clinical Pharmacology and Therapeutics|September 20, 2025
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine TherapyMichael T Eadon, David W Hein, Michael A Andersen, et al.
The New England Journal of Medicine|November 18, 2014
Blood pressure in early autosomal dominant polycystic kidney diseaseRobert W Schrier, Kaleab Z Abebe, Ronald D Perrone, et al.
Pageof 102